Goldman Sachs Maintains Buy on Blueprint Medicines, Raises Price Target to $168
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Terence Flynn maintains a Buy rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $121 to $168.
May 06, 2024 | 3:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs maintains a Buy rating on Blueprint Medicines and increases the price target to $168, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst like Goldman Sachs typically signals a strong conviction in the company's future performance, potentially leading to increased investor confidence and a positive short term price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100